Huateng Pharma Announced To Present CPhI North America In April 2023

March 11, 2023

A world-leading company in PEG derivatives and pharmaceutical intermediates named Hunan Huateng Pharmaceutical Co., Ltd (hereinafter referred to as Huateng Pharma) recently announced its attendance at the upcoming CPHI North America 2023. This three-day event will take place at Pennsylvania Convention Center, Philadelphia from 25th-27th April, 2023.

 

Huateng Pharma is a one-stop contract development and manufacturing organization (CDMO) for PEG derivatives and pharmaceutical intermediates from clinical supply to commercial scale. We have established a 5000 square meters R&D center , equipped with nearly 100 sets of high-end analytical and testing instruments and automatic reaction equipment. We also have a 34,000 square meter manufacturing site with advanced design concept of intelligent manufacturing, which can realize the integration of the production process and accomplish the complete transformation of lab scale - pilot plant - large-scale commercial production.

 

“We are very much looking forward to attending this CPhI North America, which will give us the opportunity to learn from the best minds of the chemical world, and we also have the chance to communicate with new and existing customers and learn more about each other. "said a senior manager at Huateng Pharma. "We look forward to interacting with our customers face to face, sharing updates on our plant's progress and presenting our plant's capacity."

 

Basic Information about the CPHI North America 2023

 

Date: 25-27 April, 2023,

Booth NO.: Booth# 322

Location: Philadelphia, Pennsylvania, USA.

 

Huateng Pharma, founded in 2013, is a one-stop contract development and manufacturing organization (CDMO) to manufacture and supply researchers with pharmaceutical intermediates, PEG raw materials & PEG derivatives and products used across the pharmaceutical value chain including intermediates, excipients, APIs, and reagents.

 

Pharmaceutical Intermediates: Offer pharma intermediates'process development and scale-up production with capacities varying from gram to kilograms and multi tons.

 

PEG Deriavtives: Stock of 3000+ high-quality PEG derivatives, monodispersed PEG linkers, multi-arm PEGs from R&D through GMP commercial scale.